Redpin Therapeutics, a privately held, preclinical-stage gene therapy company, is creating a proprietary chemogenetics platform to develop targeted cell therapies addressing currently intractable diseases of the nervous system.
Nine months after project completion, Redpin was acquired by Kriya Therapeutics.
We opted for our Main 3D animation type for this project because it can showcase the technology from the body down to the molecular level, making it an effective tool for communicating complex scientific concepts. It also has a cinematic quality, which captivates audiences and effectively conveys any mechanism of action. This makes it the ideal choice for projects where both scientific accuracy and the ability to attract and retain audience attention are critical, such as visuals for investor relations and communications with key opinion leaders.